Latest Regulatory News

Australian Rare Earths Limited has launched a significant 2025 drilling campaign at its Overland Uranium Project, targeting promising palaeovalley structures and high-priority zones following encouraging 2024 results. Regulatory approvals for the Sheer Gold Farm-In further expand exploration potential.

Acrux Limited announces the retirement of CEO Michael Kotsanis after more than 10 years at the helm, with a search underway for his successor to lead the next phase of growth.

Cygnus Metals has secured conditional approval for up to C$1.3 million from Canada’s Critical Minerals Infrastructure Fund to support key pre-construction milestones at its Chibougamau Copper-Gold Project, marking a significant step towards feasibility and infrastructure development.

Lanthanein Resources has completed diamond drilling at its Lady Grey Project, targeting a significant EM conductor plate aligned with gold anomalies. Approval for further drilling under a higher-grade anomaly sets the stage for potential resource expansion.

Evion Group has raised $2 million through a Rights Issue and Shortfall Placement to accelerate expansion of its Panthera Graphite JV, aiming to double production capacity amid strong global demand.

Medallion Metals has secured a positive EPBC Referral decision for its Ravensthorpe Gold Project, marking a crucial milestone in its sulphide development strategy. The company aims to submit additional environmental data by March 2025, targeting final approval by Q3 2025 while progressing drilling and financing.

New World Resources has secured a critical federal permitting milestone for its Antler Copper Project, setting a clear path to full approval within 12 months and construction commencement in H2 2025.

Atlas Arteria reveals it will face a significant temporary supplemental tax under France’s new 2025 Finance Law, impacting its APRR Group operations with payments due late next year.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Nick Scali Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the six months ending December 2024, signaling steady shareholder returns.

News Corporation reported a robust half-year performance with revenues up 4% to $4.33 billion and net income soaring 80% to $334 million, while advancing its strategic pivot through the planned sale of Foxtel.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.